Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical is viewed positively because its core spine franchise, Enabling Technologies growth, and acquisition-led scale from NuVasive and Nevro support a durable earnings trajectory despite temporary revenue disruptions. In 3Q26, revenue was $764M versus $792M consensus, yet EPS of $1.23 beat $1.20 and adjusted EBITDA margin reached 34.3%, with gross margin at 69.5%, underscoring strong operating leverage and synergy capture. Management’s lowered 2026 revenue guide reflects delayed launches and weaker near-term Nevro contribution, but the long-term case rests on resumed growth in 2027, mid-single-digit organic expansion, and continued margin improvement.

Globus Medical is facing a negative outlook because the NuVasive and Nevro mergers could create integration disruption and revenue dis-synergies just as the spine market may slow or face reimbursement and pricing headwinds. The company also faces intensified competition from more focused spinal franchises, while weaker-than-expected adoption of imaging and other systems or slower rollouts into trauma, hips, and knees could limit growth and delay diversification. On top of that, if the Enabling Technologies segment sees slower robotic purchasing or operating margins decline materially, estimates would be at risk and the stock’s fundamental setup would worsen.